Abstract
Improving clinical care for individuals infected with SARS-CoV-2 variants is a global health priority. Small-molecule antivirals like remdesivir (RDV) and biologics such as human monoclonal antibodies (mAbs) have demonstrated therapeutic efficacy against SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19). It is not known whether combination RDV/mAb will improve outcomes over single-agent therapies or whether antibody therapies will remain efficacious against variants. Here, we show that a combination of two mAbs in clinical trials, C144 and C135, have potent antiviral effects against even when initiated 48 h after infection and have therapeutic efficacy in vivo against the B.1.351 variant of concern (VOC). Combining RDV and antibodies provided a modest improvement in outcomes compared with single agents. These data support the continued use of RDV to treat SARS-CoV-2 infections and the continued clinical development of the C144 and C135 antibody combination to treat patients infected with SARS-CoV-2 variants.
Keywords: B.1.351; COVID-19; RDV; SARS-CoV-2; monoclonal antibodies; remdesivir; therapy; variants.
【저자키워드】 COVID-19, SARS-CoV-2, therapy, B.1.351, Remdesivir, monoclonal antibodies, variants, RDV, 【초록키워드】 coronavirus disease, Coronavirus disease 2019, Antiviral, antibody, VoC, B.1.351, SARS-COV-2 infection, variant, Infection, Remdesivir, clinical trials, outcome, monoclonal antibodies, variants, Antiviral effect, Health, SARS-CoV-2 variants, Human monoclonal antibody, Patient, clinical care, in vivo, SARS-CoV-2 infections, mAbs, monoclonal, mAb, human monoclonal antibodies, Combination, causative agent, Support, B.1.351 variant, These data, individual, therapeutic efficacy, clinical development, treat, antibody combination, IMPROVE, provided, demonstrated, initiated, Improving, infected with SARS-CoV-2, 【제목키워드】 prevention, mice,